Physician profile
Sandra Jo Higgs
NPI 1306999610
$8,694.29
in general payments reported to CMS, 2019-2025
25 companies · $3,510 in 2025
The $3,510 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $401 · 2023: $1,884 · 2024: $2,735 · 2025: $3,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,127.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,405.81 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,509.44 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $994.66 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $576.67 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $538.60 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $454.64 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $440.90 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $388.03 | 2023-2025 | Auvelity, Sunosi |
| Harmony Biosciences LLC | $342.46 | 2023-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $262.96 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $156.05 | 2024-2025 | Cobenfy |
| Corium, LLC | $133.37 | 2023-2025 | Azstarys, Azstarys |
| Idorsia Pharmaceuticals US INC | $110.25 | 2023-2025 | Quviviq, Quviviq |
| Janssen Pharmaceuticals, INC | $87.63 | 2023-2025 | Spravato, Invega Sustenna, Invega |
| Supernus Pharmaceuticals, INC. | $87.14 | 2023-2025 | Qelbree, Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $54.54 | 2023-2024 | Loreev Xr |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.71 | 2023 | Aplenzin |
| Collegium Pharmaceutical, INC. | $22.79 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $16.32 | 2023 | Jornay Pm |
| Lilly USA, LLC | $16.23 | 2025 | Kisunla |
| Bausch Health US, LLC | $14.66 | 2023 | Wellbutrin, Aplenzin |
| Janssen Biotech, INC. | $14.53 | 2023 | |
| Indivior INC. | $14.50 | 2023 | Perseris |
| Alkermes, INC. | $13.96 | 2023 | Lybalvi |
| Avanir Pharmaceuticals, INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Higgs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.